TrialFrontiers in immunology2026

SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.

Lin Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.